| Name | Title | Contact Details |
|---|
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox`s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.
Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...